Cyclic GMP phosphodiesterase

Details Cyclic GMP phosphodiesterase Cyclic GMP phosphodiesterase

2005-02-22

2005-02-22

Huff, Sheela J. (Department: 1642)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023500, C530S350000, C435S069100, C435S071100, C435S320100, C435S006120

Reexamination Certificate

active

06858714

ABSTRACT:
The invention provides a human cyclic GMP phosphodiesterase (PDE9A) and polynucleotides which identify and encode PDE9A. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PDE9A.

REFERENCES:
patent: 5922595 (1999-07-01), Ficher et al.
patent: WO 97 35989 (1997-10-01), None
Database EST Accession No. AA502909 (8/97).*
Database EST Accession No. AA535891 (8/97).*
Skolnick et al TIBTECH vol. 18 p. 34 (1/00).*
Beavo, J.A., “Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms”,Physiological Reviews,75: 725-748 (1995).
Verghese, M.W. et al., “Regulation of Distinct Cyclic AMP-Specific Phosphodiesterase (Phosphodiesterase Type 4) Isozymes in Human Monocytic Cells”,Mol. Pharmacol.,47: 1164-1171 (1995).
Angel, J.B. et al., “Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication”,AIDS,9: 1137-1144 (1995).
Sommer, N. et al., “The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis”,Nat. Med.,1: 244-248 (1995).
Sasaki, H. et al., “Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperido”,Eur. J. Pharmacol.,282: 71-76 (1995).
Banner, K.H. and C.P. Page, “Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma”,Eur. Respir. J.,8: 996-1000 (1995).
Bang, Y.-J. et al., “Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP”,Proc. Natl. Acad. Sci. USA,91: 5330-5334 (1994).
Matousovic, K. et al., “Inhibitors of Cyclic Nucleotide Phosphodiesterase Isozymes Type-III and Type-IV Suppress Mitogenesis of Rat Mesangial Cells”,J. Clin. Invest.,96: 401-410 (1995).
Joulain, C. et al., “Influence of polyunsaturated fatty acids on lipid metabolism in human blood mononuclear cells and early biochemical events associated with lymphocyte activation”,J. Lipid Mediat. Cell Signal.,11: 63-79 (1995).
Deonarain M.P. and A. Epenetos, “Targeting enzymes for cancer therapy: old enzymes in new roles”,Br. J. Cancer,70: 786-794 (1994).
Davis, R. and Y. Qiu, (Direct Submission), GenBank Sequence Database (Accession X55167, S70588, S70600, X55247), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894 (GI 7897; GI 829179), 1993.
Qiu, Y. et al., “Characterization of the Memory Gene Dunce ofDrosophila melanogaster”, J. Mol. Biol.,222: 553-565 (1991), (GI 7897; GI 829179).
Segel, I.H.,Enzyme Kinetics,John Wiley and Sons, New York, NY, pp. 214-245 (1995).
National Cancer Institute, Cancer Genome Anatomy Project: “Homo sapienscDNA clone IMAGE:900018 similar to WP:R153.1 CE02038 Cyclic Nucleotide Phosphodiesterase,” (Acc. No. AA502909) (GI 2237876), Jul. 4, 1997.
Fisher, D.A. et al., “Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase,”J. Biol. Chem.,273(25):15559-15564 (1998).

Affiliated with

Also associated with

Rating

Cyclic GMP phosphodiesterase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic GMP phosphodiesterase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic GMP phosphodiesterase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3501170